4-Star Stocks Poised to Pop: Novo Nordisk

Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, Danish drug giant Novo Nordisk (NYS: NVO) has earned a respected four-star ranking.

With that in mind, let's take a closer look at Novo's business and see what CAPS investors are saying about the stock right now.

Novo facts

Headquarters (founded)

Bagsvaerd, Denmark (1925)

Market Cap

$81.7 billion



Trailing-12-Month Revenue

$11.3 billion


CEO Lars Sorensen (since 2000)
CFO Jesper Brandgaard (since 2000)

Return on Equity (average, past 3 years)


Cash / Debt

$2.2 billion / $147.2 million

Dividend Yield



Sources: S&P Capital IQ and Motley Fool CAPS.

On CAPS, 96% of the 560 members who have rated Novo believe the stock will outperform the S&P 500 going forward.

A few months ago, one of those Fools, silverbare, succinctly summed up the bull case for our community:

Great R&D. Has 63% of the [insulin market] in China already and diabetes is and will continue to grow there as the middle class grows and increasing adopt a "Western" style diet. Same for India. [Novo] pays a great dividend. ... Add in share price [compound annual growth] over the most recent 10 years and you get a fabulous TOTAL RETURN.

If you want market-thumping returns, you need to put together the best portfolio you can. Owning exceptional stocks is a surefire way to secure your financial future. Of course, despite a strong four-star rating, Novo may not be your top choice.

We've found another stock we are incredibly excited about -- excited enough to dub it "The Motley Fool's Top Stock for 2012." We have compiled a special free report for investors to uncover this stock today. The report is 100% free, but it won't be here forever, so click here to access it now.

Want to see how well (or not so well) the stocks in this series are performing? Follow theTrackPoisedToCAPS account.

The article 4-Star Stocks Poised to Pop: Novo Nordisk originally appeared on Fool.com.

Fool contributor Brian Pacampara owns no position in any of the companies mentioned. Motley Fool newsletter services have recommended buying shares of Pfizer. Try any of our Foolish newsletter services free for 30 days.We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Fool's disclosure policy always gets a perfect score.

Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.